TABLE 1.

Baseline demographic and clinical characteristics and biomarker values.

	SCI (n = 49)	MCI (n = 159)	Dementia (n = 101)	P‐Value
Age (years), M (SD)	68.9 (9.3)	68.2 (9.3)	67.4 (9.9)	0.623
Sex (female), n (%)	26 (53%)	82 (52%)	43 (43%)	0.311
Education (years), M (SD)	16.4 (3.6)	14.8 (4.0)	15.2 (3.0)	0.033
Race/ethnicity				0.001
Asian, n (%)	12 (24%)	21 (13%)	8 (8%)
Non‐Hispanic Black, n (%)	2 (4%)	6 (4%)	3 (3%)
Hispanic, n (%)	13 (27%)	25 (16%)	12 (12%)
Non‐Hispanic White, n (%)	22 (45%)	107 (67%)	78 (77%)
APOE e4 allele, n/total n (%)	13/46 (28%)	49/152 (32%)	34/96 (35%)	0.697
AD spectrum syndrome, n (%)	–	72 (45%)	48 (48%)	0.799
No. of longitudinal visits, M (SD)	2.8 (0.9)	2.6 (0.8)	2.3 (0.5)	<0.001
Years since baseline (longitudinal visits only), M (SD)	2.7 (1.6)	1.9 (1.1)	1.4 (0.7)	<0.001
CDR‐SB, M (SD)	0.26 (0.53)	2.04 (1.42)	5.89 (2.29)	<0.001
Plasma Aβ42/40 (pg ml−1), M (SD)	0.07 (0.01)	0.07 (0.01)	0.06 (0.01)	0.029
Plasma pTau181 (pg ml−1), M (SD)	1.57 (0.69)	2.03 (1.05)	2.47 (1.41)	<0.001 *
Plasma NfL (pg ml−1), M (SD)	23.59 (12.97)	29.67 (24.77)	42.36 (39.15)	<0.001 *
Plasma GFAP (pg ml−1), M (SD)	126.52 (56.04)	163.93 (106.54)	206.59 (125.68)	<0.001 *
TabCAT‐BHA Cognitive Composite, M (SD)	−0.71 (1.19)	−2.30 (1.74)	−3.99 (1.95)	<0.001

Note: Group differences were examined using analyses of variance for continuous outcomes and Fisher's exact tests for categorical outcomes.

Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein E; CDR‐SB, Clinical Dementia Rating Scale Sum of Boxes; M, mean; MCI, mild cognitive impairment; NfL, neurofilament light; SCI, subjective cognitive impairment; SD, standard deviation; TabCAT‐BHA, Tablet‐based Cognitive Assessment Tool Brain Health Assessment.

^* P‐values are based on natural log‐transformed plasma pTau181, NfL, and GFAP values.